NYSEAMERICAN:CCEL Cryo-Cell International (CCEL) Stock Price, News & Analysis → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free CCEL Stock Alerts $8.29 -0.02 (-0.24%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$8.01▼$8.5550-Day Range$5.03▼$6.1452-Week Range$3.67▼$8.67Volume9,392 shsAverage Volume9,713 shsMarket Capitalization$67.15 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestStock AnalysisChartDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort Interest Get Cryo-Cell International alerts: Email Address Ad Porter & Company#1 election stockI’ve found the number one company to buy… Before either Trump or Biden wins in November. It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power. For the full story, click here. About Cryo-Cell International Stock (NYSEAMERICAN:CCEL)Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.Read More CCEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CCEL Stock News HeadlinesApril 15, 2024 | msn.comCCEL Stock Earnings: Cryo-Cell International Beats EPS, Misses Revenue for Q1 2024April 15, 2024 | businesswire.comCord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2024 Financial ResultsMay 2, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”March 26, 2024 | markets.businessinsider.comCryo-Cell Plans To Explore Strategic Alternatives And Spin-off Of Celle SubsidiaryMarch 23, 2024 | finance.yahoo.comCryo-Cell International, Inc. (CCEL)March 14, 2024 | msn.comUnveiling the Molecular Dance Capturing the Activation of Cell Receptors through Cryo-Electron MicroscopyFebruary 28, 2024 | businesswire.comCryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2023February 14, 2024 | wsj.comCryo-Cell International Inc.May 2, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”February 5, 2024 | seekingalpha.comInvitae plunges amid report it may file for bankruptcy within weeks (update)October 14, 2023 | markets.businessinsider.comStrong Performance and Growth Potential Drive Buy Rating for Cryo-Cell International: An Analysis by Allen KleeOctober 12, 2023 | finance.yahoo.comCord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2023 Financial ResultsAugust 31, 2023 | benzinga.comCryo-electron Microscopy Market worth $2.1 billion by 2028July 19, 2023 | markets.businessinsider.comMaxim Group Keeps Their Buy Rating on Cryo-Cell International (CCEL)July 14, 2023 | finance.yahoo.comCord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2023 Financial ResultsMay 4, 2023 | marketwatch.comStem Cell Services Market to Receive Overwhelming Hike in Revenues by 2030 With key Players Paragon Bioservices, APEX Biologix, VcanBio, Cryo-cellApril 28, 2023 | marketwatch.comCell Banking Outsourcing Market Research Analysis 2023-2031April 27, 2023 | marketwatch.comGlobal Cord Blood Stem Cells Market by [2023-2029] with Revenue OutsourcingApril 24, 2023 | msn.comLooking Into Cryo-Cell International's Return On Capital EmployedApril 21, 2023 | msn.comCPS Technologies CEO resignsApril 21, 2023 | msn.comCRYO-CELL International GAAP EPS of $0.09 beats by $0.13, revenue of $7.82M beats by $0.41MApril 21, 2023 | finance.yahoo.comCord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2023 Financial ResultsMarch 30, 2023 | marketwatch.com2023-2029 Cord Stem Cell Banking Market Size and Industrial Analysis with Market Dynamics | Latest Report by Absolute ReportsMarch 22, 2023 | marketwatch.comCell Banking Outsourcing Market Outlook by 2031March 1, 2023 | msn.comCRYO-CELL International GAAP EPS of $0.33 beats by $0.20, revenue of $30.3M beats by $0.46MMarch 1, 2023 | finance.yahoo.comCryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2022February 22, 2023 | seekingalpha.comCCEL Cryo-Cell International, Inc.See More Headlines Receive CCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cryo-Cell International and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/15/2024Today5/02/2024Fiscal Year End11/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A Current SymbolNYSEAMERICAN:CCEL CUSIPN/A CIK862692 Webwww.cryo-cell.com Phone(813) 749-2100Fax813-855-4745Employees82Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,520,000.00 Net Margins-31.02% Pretax Margin-43.94% Return on Equity-64.31% Return on Assets5.47% Debt Debt-to-Equity RatioN/A Current Ratio0.49 Quick Ratio0.45 Sales & Book Value Annual Sales$31.34 million Price / Sales2.14 Cash Flow$0.66 per share Price / Cash Flow12.60 Book Value($1.28) per share Price / Book-6.48Miscellaneous Outstanding Shares8,100,000Free Float5,263,000Market Cap$67.15 million OptionableNot Optionable Beta0.45 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. David I. Portnoy (Age 61)Chairman & Co-CEO Comp: $1.45MMr. Mark L. Portnoy (Age 60)Co-CEO & Director Comp: $990kMs. Jill M. Taymans (Age 54)CFO & VP of Finance Comp: $254.77kMr. Oleg Mikulinsky (Age 51)Chief Information Officer Comp: $382.77kDr. Joanne Kurtzberg M.D.Medical Director and Member of Medical & Scientific Advisory BoardKey CompetitorsCurative BiotechnologyOTCMKTS:CUBTCarisma TherapeuticsNASDAQ:CARMInstil BioNASDAQ:TILFSD PharmaOTCMKTS:FSDDFenVVeno MedicalNASDAQ:NVNOView All CompetitorsInstitutional OwnershipMassmutual Trust Co. FSB ADVSold 3,178 shares on 4/9/2024Ownership: 1.339%Rowlandmiller & PARTNERS.ADVBought 14,433 shares on 4/8/2024Ownership: 0.174%View All Institutional Transactions CCEL Stock Analysis - Frequently Asked Questions Are investors shorting Cryo-Cell International? Cryo-Cell International saw a decline in short interest in April. As of April 15th, there was short interest totaling 16,900 shares, a decline of 22.8% from the March 31st total of 21,900 shares. Based on an average daily volume of 10,600 shares, the days-to-cover ratio is presently 1.6 days. Currently, 0.4% of the shares of the company are sold short. View Cryo-Cell International's Short Interest. How were Cryo-Cell International's earnings last quarter? Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) announced its earnings results on Monday, April, 15th. The company reported $0.07 EPS for the quarter. The business had revenue of $7.85 million for the quarter. Cryo-Cell International had a negative net margin of 31.02% and a negative trailing twelve-month return on equity of 64.31%. Who are Cryo-Cell International's major shareholders? Cryo-Cell International's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Massmutual Trust Co. FSB ADV (1.34%) and Rowlandmiller & PARTNERS.ADV (0.17%). View institutional ownership trends. How do I buy shares of Cryo-Cell International? Shares of CCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:CCEL) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace😱 This phenomenon is smashing regular market gainsMillPubA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingForget Nvidia. This is the future of AIPorter & CompanyAI “wealth window” is closing June 25thParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cryo-Cell International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
